Having trouble accessing articles? Reset your cache.

Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

The most recent long-term data for bluebird bio's Zynteglo β thalassemia gene therapy show that about 80% of patients could hit payment milestones based on details the biotech disclosed about its outcomes-based pricing model on Friday.

bluebird bio Inc. (NASDAQ:BLUE) presented long-term follow-up data Friday from the Phase I/II Northstar (HGB-204) trial that showed in 10 β thalassemia patients without the β0/β0 genotype -- in line with Zynteglo's approved indication in Europe -- eight met the primary endpoint of transfusion independence, with the longest duration

Read the full 844 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE